The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review
2024

Cholic Acid Treatment for Bile Acid Synthesis Defects

Sample size: 162 publication Evidence: low

Author Information

Author(s): Polak Yasmin, van Dussen Laura, Kemper E. Marleen, Vaz Frédéric M., Klouwer Femke C. C., Engelen Marc, Hollak Carla E. M.

Primary Institution: Amsterdam UMC, University of Amsterdam

Hypothesis

Cholic acid supplementation is hypothesized to decrease bile acid production, stimulate bile secretion and flow, and slow down disease progression in patients with bile acid synthesis defects.

Conclusion

More controlled studies are required as the available data is insufficient to draw definite conclusions on the effectiveness and safety of cholic acid treatment in bile acid synthesis defect patients.

Supporting Evidence

  • Cholic acid treatment has been authorized as an orphan drug in the EU for certain bile acid synthesis defects.
  • Studies show that CA treatment reduces concentrations of toxic bile acid intermediates in plasma.
  • Most studies reported aggregated data, presenting overall group results without differentiating for disease type.

Takeaway

This study looked at how well cholic acid works for people with certain rare diseases that affect bile acids. It found that we need more studies to really know if it helps.

Methodology

A systematic review of MEDLINE, Embase, and clinical trial registries using controlled MeSH- and Emtree terms.

Potential Biases

The overall risk of bias score was considered critical for one study, serious for four studies, and moderate for nine studies.

Limitations

The studies had severe limitations including small sample sizes, lack of controls, and missing data.

Participant Demographics

The included population concerned patients with Zellweger spectrum disorders (n=73), 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency (n=62), cerebrotendinous xanthomatosis (n=22), Δ4-3-oxosteroid 5β-reductase deficiency (n=13), and α-methylacyl-CoA racemase deficiency (n=3).

Digital Object Identifier (DOI)

10.1186/s13023-024-03449-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication